Biotechnology
Neogen® Petrifilm® Celebrates 40 Years!
LANSING, Mich., May 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) is celebrating 40 years of Petrifilm, the innovation that changed how microbiologists around the world perform indicator testing. "In the food safety industry, Petrifilm is recognized as a true game-changer," saidJohn...
2024-05-01 20:45
674
ArisGlobal Helps Boehringer Ingelheim Transform Safety Signal Processing by Leveraging Latest LifeSphere Solutions
LifeSphere Clarity drives efficiencies and reinvents the way Boehringer Ingelheim's pharmaceutical operations approach safety signals BOSTON, May 1, 2024 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, announced today that research-driven g...
2024-05-01 20:00
789
Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry
BEIJING, May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. have innov...
2024-05-01 17:14
684
Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 1, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimula...
2024-05-01 08:01
1059
Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations
SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105...
2024-04-30 23:00
1409
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-C...
2024-04-30 20:55
944
A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs
NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to co...
2024-04-30 20:16
935
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
* The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance * Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unifiedplatform for efficient global commerciali...
2024-04-30 19:00
1288
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
* Delivered solid performance to start 2024, with record-breaking first quarter revenue of34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. * Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected to be initiated in th...
2024-04-30 19:00
667
Innovation showcase displays growing influence
BEIJING, April 30, 2024 /PRNewswire/ -- A news report from China Daily:
2024-04-30 17:41
944
BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report
Three-part report investigates rapid pipeline growth, partnerships, clinical trials, and patient access challenges in cancer treatment LONDON, April 30, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, explores the ...
2024-04-30 15:00
705
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune,...
2024-04-30 12:30
1391
WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
* The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. * The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction of Scope 1 and Scope 2 greenhouse gas ...
2024-04-30 10:55
739
CARsgen Submitted Responses to FDA Observations
SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that responses regarding the status of the Corrective and Preventive...
2024-04-29 20:50
737
Henlius Trastuzumab Receives FDA Approval in the United States
SHANGHAI, April 29, 2024 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord BioPharma Inc. (the U.S. specialty division of Intas Pharmaceuticals, Ltd.), has received approval from the United States Food and Drug Administration (FDA) for ...
2024-04-29 20:18
1641
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
GAITHERSBURG, Md., April 29, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
2024-04-29 20:00
1013
Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial
CHENGDU, China, April 29, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing patients in its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment. This clinical trial in t...
2024-04-29 20:00
834
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
GAITHERSBURG, Md., April 29, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
2024-04-29 20:00
866
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
* Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8% * Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reached RMB0.66 * Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Re...
2024-04-29 19:00
1382
Angel Yeast Publishes 2023 Corporate Social Responsibility Report
SHANGHAI, April 29, 2024 /PRNewswire/ -- Angel Yeast
2024-04-29 19:00
1166
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2924
